GO-203-2C Uses, Dosage, Side Effects and more
GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
| Trade Name | GO-203-2C |
| Generic | GO-203-2C |
| Type | |
| Formula | C89H170N52O20S2 |
| Weight | Average: 2352.8 Monoisotopic: 2351.33253843 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
